HVEM/TNFRSF14 hFc Chimera, Human
HVEM/TNFRSF14 HFc Chimera, Human

Immobilized Human BTLA, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for HVEM/TNFRSF14 hFc Chimera, Human, hFc Tag with the EC50 of 27.2 ng/ml determined by ELISA.

HVEM/TNFRSF14 HFc Chimera, Human

HVEM/TNFRSF14 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

HVEM/TNFRSF14 HFc Chimera, Human

Immobilized Human LIGHT, His Tag at 2 μg/ml(100 μl/well) on the plate. Dose response curve for HVEM/TNFRSF14 hFc Chimera, Human, hFc Tag with the EC50 of 18.2 ng/ml determined by ELISA.

HVEM/TNFRSF14 HFc Chimera, Human

Human HVEM, hFc Tag captured on CM5 Chip via Protein A can bind Human CD160, His Tag with an affinity constant of 1.44 μM as determined in SPR assay (Biacore T200).

HVEM/TNFRSF14 hFc Chimera, Human

Herpesvirus entry mediator (HVEM), also known as tumor necrosis factor receptor superfamily member 14 (TNFRSF14), is a human cell surface receptor of the TNF-receptor superfamily. Two TNF superfamily ligands lymphotoxin α (TNF-β) and LIGHT (TNFSF14) are identified as cellular ligands for HVEM and initiate the positive signaling.
Z05388
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
HVEM/TNFRSF14 (Leu39-Val202)
Accession # Q92956-1		 hFc
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 44.3 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 60-70 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • HVEM/TNFRSF14 HFc Chimera, Human
    • HVEM/TNFRSF14 HFc Chimera, Human

    Immobilized Human BTLA, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for HVEM/TNFRSF14 hFc Chimera, Human, hFc Tag with the EC50 of 27.2 ng/ml determined by ELISA.

  • HVEM/TNFRSF14 HFc Chimera, Human
    • HVEM/TNFRSF14 HFc Chimera, Human

    HVEM/TNFRSF14 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

  • HVEM/TNFRSF14 HFc Chimera, Human
    • HVEM/TNFRSF14 HFc Chimera, Human

    Immobilized Human LIGHT, His Tag at 2 μg/ml(100 μl/well) on the plate. Dose response curve for HVEM/TNFRSF14 hFc Chimera, Human, hFc Tag with the EC50 of 18.2 ng/ml determined by ELISA.

  • HVEM/TNFRSF14 HFc Chimera, Human
    • HVEM/TNFRSF14 HFc Chimera, Human

    Human HVEM, hFc Tag captured on CM5 Chip via Protein A can bind Human CD160, His Tag with an affinity constant of 1.44 μM as determined in SPR assay (Biacore T200).


Background
Target Background Herpesvirus entry mediator (HVEM), also known as tumor necrosis factor receptor superfamily member 14 (TNFRSF14), is a human cell surface receptor of the TNF-receptor superfamily. Two TNF superfamily ligands lymphotoxin α (TNF-β) and LIGHT (TNFSF14) are identified as cellular ligands for HVEM and initiate the positive signaling.
Synonyms CD270; CD40-like protein; HVEM; LIGHTR; ATAR; TNFRSF14; TR2

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.